Nov 13, 2024 / 09:00AM GMT
Martin Olin - Bergenbio ASA - Chief Executive Officer
Mutation is really characterized by having a high incidence of a negative PDL one expression, meaning that they are not likely to benefit from checkpoint inhibition. And this graph shows that STK 11 actually has the higher number, highest number of a negative PDL one expression.
Also newly announced data confirms that the significant unmet medical need is actually relevant from a number of medical viewpoints. One is the overall response rate which is significantly lower than the wild type situation, but also which is very meaningful for the patients is that even if you would respond, the immediate overall or progression free survival over survival is significantly lower than the wild type with statistical significance. So, this all points to what I said before, a significant nonmed medical need and no targeted therapies available.
This translates into a significant market opportunity in the Western world. We believe this is around 30,000 patients on an annual basis that will be eligible for the treatment, combination of the sentiment
Q3 2024 Bergenbio ASA Earnings Call Transcript
Nov 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers